News and History of the Company
European Commission grants Astraveus a 1.97 M€ funding
February 28th 2019
Following a competitive selection process based on a written application and a pitch, the European Commission decided to support Astraveus for the LAKHESYS project with a subvention of 1.972M€. The contract was signed on the 28th of February 2019. This funding is a major event in our project.
In addition to the grant we benefitted from EIC (European Innovation Council) coaching support: an EIC business innovation coach, Dr. Iordanis Arzimanoglou has worked closely with ASTRAVEUS for six days on strategy reviews, advices and expert insights. This was a great help to readjust our strategy.
Finally, this grant means ASTRAVEUS becomes part of theEIC community, a network of innovative European compagnies comprising many exciting events and potential for collaborations.
MEDICEN and BPI France support Astraveus H2020 Project
In 2018 Astraveus prepared an ambitious application to the European Commission Horizon 2020 program. MEDICEN helped Astraveus by reviewing its application and deciding to officially support it. They also agreed to pay for a specialist consultant from Novanexia to review our application file. BPI France also supported us by funding a pitch training.
Astraveus wins i-Lab 2018
July 31st 2018
BPI France renews its trust in Astraveus by awarding a prize of 200k€ to fund the development of LAKHESYS. This prize was awarded under the i-Lab program, a 20 years old annual start-up contest which is in fact a major funding of French early stage start-ups. 63 other prizes were attributed in 2018 after a competitive selection.
X-Grant Silicon Valley Prize
Friends of Ecole Polytechnique and Fondation de l'Ecole Polytechnique, two alumni associations of Ecole Polytechnique, selected Astraveus project as one of the two winners of a 50k$ prize for innovation and entreupreunership. This award was key to our project funding in 2018. Along with the prize money we benefited from access to Polytechnique alumni network in the US as well as a nice public exposure.
Paris Biotech Santé incubates ASTRAVEUS
Paris Biotech Santé, a famous French Healthtech incubator, decided to incubate ASTRAVEUS after a selection process comprising a business case and a pitch. In this context Paris Biotech Santé provides us with financial help and coaching, as well as the access to a large community of life science companies.
ASTRAVEUS is Finalist of Paris Grand Prix de l'Innovation
Sadly we didn't win, but we made it to the final. Paris Grand Prix de l'Innovation is a yearly event fostering the Parisian Start-Up community. Being a finalist still gave us a nice media exposure and was nice opportunity for us to meet other startups. Congratulations to the Healthcare winners, Therapanacea !
ASTRAVEUS joins ESPCI incubator
The ESPCI (Ecole Supérieure de Physique et de Chimie Industrielle de Paris), one of the best French Engineering schools, decided to support Astraveus by letting it join its incubator, PC'up. Astraveus applied and was selected by ESPCI based on a scientific and a business case, both of which were reviewed by experts, and based on a pitch session. The incubation means we can rent beautiful offices in downtown Paris for a reduced price, access to a lot of technical facilities of the IPGG (Institut Pierre-Gilles de Gennes, an institute dedicated to microfluidics), a lot of other types of supports, and that we join an incredible start-up community with members such as Innorevia, Kapsera, MilliDrop, LightOn, Iconeus, Abbelight, Greenerwave and Cyprio.
BPI France grants ASTRAVEUS a Bourse French Tech of 45k€
August 3rd 2017
BPI France is French public investment bank. In August 2018 it granted Astraveus a 45k€ Bourse French Tech to fund our research and development plan for the development of Lakhesys instrument technologies. We are thankful for BPI's trust in funding our project at such an early stage.
WILCO accelerates ASTRAVEUS
We were selected by the Healthcare accelerator of WILCO. WILCO supported our project in many ways, notably by appointing two experienced entrepreneurs as coaches. They helped us refine our strategy. WILCO also granted to our project three "prêt d'honneur", i.e. zero interest loans of 30 000€ each. This was our first external funding and a great help to fund the first steps of our development.
ASTRAVEUS is officially registered
July 7th 2016
During his PhD at Cell Therapy unit of St Louis Hospital in Paris our founder Jérémie realized how much technical improvement was necessary to make advanced therapies less expensive and to develop them more efficiently. The purpose of the company was defined then, and it is still the same today: to make advanced therapies accessible to all.
The company, originally named Superdyne Technologies was officially registered in Paris on July 7th 2016. We later realized Superdyne was also a famous dynamite brand, so we changed the name for Astraveus.